{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:07:01Z","timestamp":1788469621557,"version":"build-2803163510"},"reference-count":33,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872449"],"award-info":[{"award-number":["81872449"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"award":["81872449"],"award-info":[{"award-number":["81872449"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>EML4-ALK-positive lung cancer represents an important molecular subtype of non-small-cell lung cancer (NSCLC) that initially responds to ALK inhibitors but invariably develops resistance, highlighting the need for novel targeted therapeutic strategies. Death receptors DR4 and DR5 are frequently upregulated in malignancies and can selectively induce tumor cell apoptosis upon binding TRAIL. ISZ-sTRAIL, a trimer-stabilized soluble TRAIL fusion protein, exhibits potent antitumor effects via DR4\/DR5 signaling activation. However, the expression status of DR4\/DR5 in EML4-ALK-positive NSCLC cells and the therapeutic potential of targeting this pathway remain poorly defined. In this study, we evaluated DR4\/DR5 protein expression in EML4-ALK-positive NSCLC cells and investigated the antitumor effect of ISZ-sTRAIL produced in an Escherichia coli expression system. Our results showed that DR4 and DR5 were abundantly expressed in EML4-ALK-positive NCI-H2228 and NCI-H3122 cells compared with normal human bronchial epithelial 16HBE cells. Furthermore, ISZ-sTRAIL significantly suppressed the proliferation of NCI-H2228 and NCI-H3122 cells, with IC50 values of 4.51 \u00b1 0.22 nM and 14.98 \u00b1 3.34 nM, respectively, while showing low cytotoxicity toward normal 16HBE cells (IC50 &gt; 1 \u03bcM). Moreover, ISZ-sTRAIL induced caspase-dependent apoptosis in both cell lines via activation of extrinsic and intrinsic pathway, and these effects were markedly abrogated by the pan-caspase inhibitor Z-VAD. These findings identify DR4\/DR5 as a potential therapeutic target and provide preclinical evidence for the development of TRAIL-based strategies in the treatment of EML4-ALK-positive NSCLC.<\/jats:p>","DOI":"10.3390\/molecules31111870","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T15:57:18Z","timestamp":1780070238000},"page":"1870","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Identification of ISZ-sTRAIL Protein as a Potent Anticancer Agent for EML4-ALK-Positive Non-Small-Cell Lung Cancer"],"prefix":"10.3390","volume":"31","author":[{"given":"Junfeng","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Chemical Biology and Pharmaceutical Engineering, School of Chemistry and Chemical Engineering, Anhui University of Technology, Ma\u2019anshan 243002, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhui","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Chemical Biology and Pharmaceutical Engineering, School of Chemistry and Chemical Engineering, Anhui University of Technology, Ma\u2019anshan 243002, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Chemical Biology and Pharmaceutical Engineering, School of Chemistry and Chemical Engineering, Anhui University of Technology, Ma\u2019anshan 243002, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuping","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Chemical Biology and Pharmaceutical Engineering, School of Chemistry and Chemical Engineering, Anhui University of Technology, Ma\u2019anshan 243002, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1353-4461","authenticated-orcid":false,"given":"Zi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Chemical Biology and Pharmaceutical Engineering, School of Chemistry and Chemical Engineering, Anhui University of Technology, Ma\u2019anshan 243002, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9131-4512","authenticated-orcid":false,"given":"Liang","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Chemical Biology and Pharmaceutical Engineering, School of Chemistry and Chemical Engineering, Anhui University of Technology, Ma\u2019anshan 243002, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation EGFR and ALK inhibitors: Mechanisms of resistance and management","volume":"19","author":"Cooper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1634\/theoncologist.2016-0488","article-title":"ALK Fusions in a wide variety of tumor types respond to anti-ALK targeted therapy","volume":"22","author":"Ross","year":"2017","journal-title":"Oncologist"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.phrs.2017.01.007","article-title":"Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41568-025-00797-9","article-title":"ALK in cancer: From function to therapeutic targeting","volume":"25","author":"Voena","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s43018-023-00515-0","article-title":"ALK-positive lung cancer: A moving target","volume":"4","author":"Schneider","year":"2023","journal-title":"Nat. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.tips.2016.10.005","article-title":"Emerging strategies for developing next-generation protein therapeutics for cancer treatment","volume":"37","author":"Kintzing","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1126\/science.276.5309.111","article-title":"The receptor for the cytotoxic ligand TRAIL","volume":"276","author":"Pan","year":"1997","journal-title":"Science"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.1093\/emboj\/16.17.5386","article-title":"TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL","volume":"16","author":"Walczak","year":"1997","journal-title":"EMBO J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s10555-018-9728-y","article-title":"Developing TRAIL\/TRAIL death receptor-based cancer therapies","volume":"37","author":"Yuan","year":"2018","journal-title":"Cancer Metastasis Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.pep.2006.07.026","article-title":"Expression, purification, and in vitro refolding of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)","volume":"51","author":"Lin","year":"2007","journal-title":"Protein Expr. Purif."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e70517","DOI":"10.1002\/cam4.70517","article-title":"Turn TRAIL into better anticancer therapeutic through TRAIL fusion proteins","volume":"14","author":"Wang","year":"2025","journal-title":"Cancer Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1021\/mp300261e","article-title":"Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: A double-target therapy against non-Hodgkin\u2019s lymphoma","volume":"10","author":"Yan","year":"2013","journal-title":"Mol. Pharm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.bbrc.2004.07.046","article-title":"The secretable form of trimeric TRAIL, a potent inducer of apoptosis","volume":"321","author":"Kim","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/sj.gt.3302658","article-title":"Cancer gene therapy using a novel secretable trimeric TRAIL","volume":"13","author":"Kim","year":"2006","journal-title":"Gene Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1158\/1535-7163.MCT-09-0202","article-title":"Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cells","volume":"8","author":"Rozanov","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41598-017-00688-6","article-title":"sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment","volume":"7","author":"Huang","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s00253-022-11807-3","article-title":"SAC-TRAIL, a novel anticancer fusion protein: Expression, purification, and functional characterization","volume":"106","author":"Zhang","year":"2022","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40265-024-02004-9","article-title":"Aponermin: First Approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"282","DOI":"10.5483\/BMBRep.2016.49.5.245","article-title":"Potentiation of TRAIL killing activity by multimerization through isoleucine zipper hexamerization motif","volume":"49","author":"Han","year":"2016","journal-title":"BMB Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.1158\/0008-5472.CAN-10-3879","article-title":"Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors","volume":"71","author":"Lovly","year":"2011","journal-title":"Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.2147\/IJGM.S512395","article-title":"Mechanisms of resistance to ALK inhibitors and corresponding treatment strategies in lung cancer","volume":"18","author":"Xie","year":"2025","journal-title":"Int. J. Gen. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Zhang, B., Zeng, J., Zhang, H., Zhu, S., Wang, H., He, J., Yang, L., Zhou, N., Zu, L., and Xu, X. (2022). Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation. Front Immunol., 13.","DOI":"10.3389\/fimmu.2022.974581"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Masroor Ali Beg, M., Aslam, M., Ayaz, A., Akhtar, M.S., and Zaman, W. (2025). Advances in non-small cell lung cancer cellular immunotherapy: A progress in dendritic cell, T-cell, and NK cell vaccines. Cells, 14.","DOI":"10.3390\/cells14181453"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbrc.2004.07.098","article-title":"Increased cytotoxicity of soluble Fas ligand by fusing isoleucine zipper motif","volume":"322","author":"Shiraishi","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Luo, C., He, S., Shi, F., Zhou, J.H., and Shang, L. (2024). The role of TRAIL signaling in cancer: Searching for new therapeutic strategies. Biology, 13.","DOI":"10.3390\/biology13070521"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"116041","DOI":"10.1016\/j.bcp.2024.116041","article-title":"Significance of TRAIL\/Apo-2 ligand and its death receptors in apoptosis and necroptosis signalling: Implications for cancer-targeted therapeutics","volume":"221","author":"Maji","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"102193","DOI":"10.1016\/j.redox.2021.102193","article-title":"TRAIL sensitivity of nasopharyngeal cancer cells involves redox dependent upregulation of TMTC2 and its interaction with membrane caspase-3","volume":"48","author":"Raman","year":"2021","journal-title":"Redox Biol."},{"key":"ref_30","first-page":"3397","article-title":"Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors","volume":"9","author":"Spierings","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"21694","DOI":"10.1074\/jbc.M116.738302","article-title":"Expression of death receptor 4 is positively regulated by MEK\/ERK\/AP-1 signaling and suppressed upon MEK inhibition","volume":"291","author":"Yao","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"100908","DOI":"10.1016\/j.neo.2023.100908","article-title":"ALK inhibitors downregulate the expression of death receptor 4 in ALK-mutant lung cancer cells via facilitating Fra-1 and c-Jun degradation and subsequent AP-1 suppression","volume":"42","author":"Zhao","year":"2023","journal-title":"Neoplasia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"101081","DOI":"10.1016\/j.drup.2024.101081","article-title":"Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome","volume":"74","author":"Ramos","year":"2024","journal-title":"Drug Resist. Updat."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/11\/1870\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:17:33Z","timestamp":1780633053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/11\/1870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["molecules31111870"],"URL":"https:\/\/doi.org\/10.3390\/molecules31111870","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]}}}